Navigation Links
Investigational anti-restenosis drug pimecrolimus disappoints
Date:3/31/2008

CHICAGO, Ill. (March 31, 2008) A new medication that researchers had hoped would reduce the risk of arterial renarrowing after stenting has turned in a disappointing performance in a multicenter clinical trial, but the multi-reservoir stent that was used to deliver the drug is still considered promising.

Pimecrolimus, an anti-inflammatory medication, was expected to reduce arterial inflammation and, therefore, the overgrowth of scar tissue, or neointimal hyperplasia, that causes in-stent restenosis. Instead, patients treated with pimecrolimus-eluting stents fared far worse than patients treated with stents that delivered a combination of pimecrolimus and paclitaxel, or paclitaxel alone, according to the Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries (GENESIS). Paclitaxel is also an anti-restenosis medication, but it works by inhibiting cell division, rather than by reducing arterial inflammation.

The GENESIS study was terminated early by its sponsors. The data gathered to that point are being reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

Despite pre-clinical data suggesting marked efficacy of pimecrolimus in suppressing neointimal hyperplasia, the extent of tissue growth and resulting rates of target vessel revascularization at six months were high in patients treated with this drug, said Stefan Verheye, MD, PhD, co-director of the catheterization laboratories at Antwerp Cardiovascular Center, ZNA Middelheim Hospital, Antwerp, Belgium.

The GENESIS study was als
'/>"/>

Contact: Kathy Boyd David
pr@scai.org
717-422-1181
Weber Shandwick Worldwide
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Investigational drug tested for preventing muscle fiber death in muscular dystrophy
2. Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib
3. New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets
4. UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam
5. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
6. MetaCure(TM) Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight
7. Abbotts Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
8. Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
9. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
10. Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract
11. Accentia announces investigational new drug application for Revimmune for refractory MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ... 06, 2015 , ... MD Now, the leading and fastest-growing urgent care provider ... care center will serve residents and visitors in the Cutler Bay area, giving them ... South Florida location, the new facility will be the fourth to serve Miami-Dade County. ...
(Date:7/6/2015)... ... July 06, 2015 , ... The School ... funds to support a three-year effort to reduce rates of diabetes and cardiovascular ... in partnership with the Morehouse School of Medicine’s Prevention Research Center and the ...
(Date:7/6/2015)... ... 06, 2015 , ... Promero, a leading cloud hosting provider ... IP contact center solution hosted by Promero. Randstad Technologies,a leading talent and ... call center platform. , Promero will implement and manage the private cloud ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... Thanks to ... Health and Hospice received the Music & Memory Certification for hospice patients and adult ... power of music not only to patients but also to their families and volunteers. ...
(Date:7/5/2015)... ... 06, 2015 , ... City Sports, the Boston-based specialty sporting goods retailer, has ... for first-time triathletes this summer with ethos, the owner and operator of the Boston ... at 6:00 p.m. at the North End Greenway. The event will help new triathletes ...
Breaking Medicine News(10 mins):Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 3Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 2Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 4Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 2Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 3
... April 5 (HealthDay News) -- No doubt timed to coincide with ... detailing a trendy new diet made famous by the French is ... The Dukan Diet has sold more than 3 million ... is publishing the book here. Created by French physician Dr. ...
... (April 5, 2011) -- Thanks to the zebrafish, there is new ... responsible for approximately 8,700 deaths each year in the United States. ... issue of the journal Nature , and featured on the ... growth of melanoma and may play a role in up to ...
... and information concerning health care for older adults will be ... Symposium, sponsored by the Department of Family and Geriatric Medicine ... symposium will be held from 7:30 a.m. to 4 p.m., ... the Rudd Heart & Lung Center at Jewish Hospital, 201 ...
... TUESDAY, April 5 (HealthDay News) -- Girls involved in high-impact ... increased risk for stress fractures, a new study finds. ... 9 to 15, in the United States. During that time, ... Girls with a family history of osteoporosis or lone ...
... academics from around the world will gather in Chicago ... premiere scientific conference in the fields of gastroenterology, hepatology, ... the conference will feature presentations of breakthrough research on ... Does BMI screening start too late ...
... , Teenagers who undergo spine fusion for scoliosis using the ... years after surgery, according to a Hospital for Special Surgery ... of the journal Spine . Researchers had thought that ... the fused discs, but the study showed that this was ...
Cached Medicine News:Health News:Can the Dukan Diet Do It? 2Health News:Can the Dukan Diet Do It? 3Health News:Researchers use zebrafish to identify new gene linked to melanoma 2Health News:Researchers use zebrafish to identify new gene linked to melanoma 3Health News:11th Annual Geriatrics Health Care Symposium set for April 22 at University of Louisville 2Health News:Girls in Some Sports Face Raised Risk of Stress Fractures: Study 2Health News:Study shows that modern surgery for scoliosis has good long-term outcomes 2Health News:Study shows that modern surgery for scoliosis has good long-term outcomes 3
(Date:7/6/2015)... 6, 2015 Mauna Kea ... multidisciplinary confocal laser endomicroscopy platform, announced today it ... Ministry of Health, Labor and Welfare (MHLW) ... the AQ-Flex 19 miniprobe.   Used ... miniprobe is comprised of a fiber-optic microscope that ...
(Date:7/6/2015)... 6, 2015   BioClinica®, Inc ., a ... announced that it has acquired a leading global ... Inc. (Medici).  The acquisition includes affiliates MediciGlobal ... also provides a lost-to-follow-up patient locate service ( ... with Medici, BioClinica will offer pharmaceutical ...
(Date:7/6/2015)... DUBLIN, Ohio , July 6, 2015 ... of The Harvard Drug Group (THDG). A distributor of generic ... and alternate care customers, THDG was owned by Court ... all-cash transaction using existing cash and new debt.  ... , The Harvard Drug Group had revenues of approximately ...
Breaking Medicine Technology:Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 3BioClinica Acquires MediciGroup 2BioClinica Acquires MediciGroup 3Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 2Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 3
... PRO-DEX, INC. (Nasdaq: PDEX ) will announce results for the Company,s fiscal ... on Thursday, April 29, 2010 after the market closes. , ... Following the release, Pro-Dex will conduct a ... ) to discuss operating performance for the quarter.  Mark Murphy, Chief Executive Officer ...
... PRINCETON, N.J. , April 23 Yesterday, ... first study comparing the once-daily human GLP-1 analog, Victoza® (liraglutide [rDNA] ... Victoza® produced significantly greater reductions in A1C, fasting plasma glucose (FPG), ... satisfaction. , , , ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2010 Third Quarter Financial Results Conference Call and Webcast 2Pro-Dex, Inc. Announces Fiscal 2010 Third Quarter Financial Results Conference Call and Webcast 3The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 2The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 3The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 4The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 5The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 6
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: